Becker muscular dystrophy

News

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Santhera seeks speedy FDA review of Duchenne drug vamorolone

Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023.

News

CNS-focused Supernus and Indivior agree merger terms

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new CNS-focused company with annual sales of $2.2bn.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Becker muscular dystrophy

Editor's Picks